Get notified of page updates

Study: Pausing hormone therapy to pursue pregnancy does not increase the short-term risk of early-stage cancer recurrence

Summary

Women who paused hormone therapy treatment of early-stage hormone receptor-positive (HR-positive) breast cancer to attempt to get pregnant had no increase in short-term recurrence. (Posted 11/3/23)

Este artículo está disponible en español.

Printer Friendly Page Read the Original Article
Pausing hormone therapy to pursue pregnancy does not increase the short-term risk of early-stage cancer recurrence
Glossary on
off

RELEVANCE

Most relevant for: Women with breast cancer who are considering pregnancy.
It may also be relevant for:

  • people with breast cancer

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Post Approval

Relevance Rating Details


Why is this research important?

Breast cancer is the most common cancer for women under age 40. Family planning and fertility is often a priority at these ages, and these concerns can affect quality of life and whether patients stay on treatment. Experts typically recommend 5-10 years of hormone therapy after surgery and chemotherapy for breast cancer. To become pregnant, hormone therapy must be discontinued or interrupted. Because fertility decreases with age, delaying conception for 5-10 years to complete hormone therapy may greatly decrease the ability to have children.

Although past research shows that pregnancy after breast cancer does not worsen outcomes, more research is needed to show that it is safe to temporarily stop treatment to become pregnant.

What is the POSITIVE trial?
The POSITIVE trial was an international study designed to learn whether it is safe to interrupt hormone treatment for breast cancer to become pregnant after a recent diagnosis of HR-positive breast cancer. Birth rates and potential pregnancy complications were also studied.

POSITIVE followed 497 participants under age 42 who interrupted their hormone therapy to try to conceive. Most  participants:

  • identified most frequently as white.
  • were 35-39 years old.
  • had 1 or 2 cancer.
  • had received chemotherapy in addition to their hormone therapy.

Of the 497 participants, 59 had a known (38 in or BRCA2; the remainder in other genes).

Study findings

  • 368 of 497 participants (68%) had at least one pregnancy.
    • Most of the women with successful pregnancies were younger.
    • Almost half of the women in the study who became pregnant used some sort of fertility treatment.
    • Pregnancy complications and birth defects occurred at rates similar to healthy women of the same age.
       
  • Overall, women who interrupted their breast cancer hormone therapy for pregnancy:
    • had no increased risk of breast cancer during the 3 years of follow-up care.
    • 9% of women in the group that interrupted treatment were diagnosed with recurring breast cancer. This number was similar to women who did not stop hormone therapy (a different study provided the statistics for the risk of recurrence in women who did not stop hormone therapy).
  • Most women with an inherited mutation did not have a cancer recurrence during this study.
    • 9 of 59 participants (15%) with an inherited mutation had a recurrence.
    • 35 of 457 participants (8%) without a known inherited mutation had a cancer recurrence.
      • Because the number of people with mutations and the number of cancer recurrences were small, it is unclear whether women with an inherited mutation had a similar or increased possibility of cancer returning. Additional research is needed to clarify this.

This study followed patients for only three years. Longer follow-up is needed to understand whether these results are similar when more time has passed since the initial diagnosis.

Find Experts
Find Experts

The following resources can help you locate an expert near you or via telehealth. 

Finding fertility experts

  • The Oncofertility Consortium maintains a national database of healthcare providers with expertise in fertility preservation and treatment of people who are diagnosed with cancer or at high risk for cancer due to an inherited mutation.  
  • Livestrong has a listing of 450 sites that offer fertility preservation options for people diagnosed with cancer. Financial assistance may be available to make the cost of fertility preservation affordable for more patients.

Other ways to find experts

Updated: 04/07/2023

Back to XRAY Home